Drug Trial Radar · NCT05181618
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
136
Actual
Start
Jun 20, 2022
Primary completion
Nov 19, 2026
Study completion Dec 21, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 13 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and \<70 years with severe hemophilia A without factor VIII (FVIII) inhibitors or moderate hemophilia A without FVIII inhibitors who are receiving FVIII prophylaxis and who will start emicizumab treatment as part of this study.
Conditions
- Severe Hemophilia A
- Moderate Hemophilia A
Interventions
EmicizumabDrug
The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Joint Status at 6 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with SynovitisTime frame: 6 Months
- Joint Status at 12 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with SynovitisTime frame: 12 Months
- Joint Status at 24 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with SynovitisTime frame: 24 Months
- Joint Status at 36 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with SynovitisTime frame: 36 Months
- Clinical Joint Status at 6 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait AssessmentTime frame: 6 Months
- Clinical Joint Status at 12 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait AssessmentTime frame: 12 Months
- Clinical Joint Status at 24 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait AssessmentTime frame: 24 Months
- Clinical Joint Status at 36 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait AssessmentTime frame: 36 Months
- Joint Status at 36 Months, Based on Centrally Reviewed International Prophylaxis Study Group (IPSG) Score (with MRI)Time frame: 36 Months
- Number of Problem Joints at 6 MonthsTime frame: 6 Months
- Number of Problem Joints at 12 MonthsTime frame: 12 Months
- Number of Problem Joints at 24 MonthsTime frame: 24 Months
- Number of Problem Joints at 36 MonthsTime frame: 36 Months
- Percentage of Joints That are Problem Joints at 6 MonthsTime frame: 6 Months
- Percentage of Joints That are Problem Joints at 12 MonthsTime frame: 12 Months
- Percentage of Joints That are Problem Joints at 24 MonthsTime frame: 24 Months
- Percentage of Joints That are Problem Joints at 36 MonthsTime frame: 36 Months
- Change from Baseline in the CATCH Domain Scores Over Time, as Assessed with the Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) Questionnaire for Adult ParticipantsTime frame: At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
- Change from Baseline in the CATCH Domain Scores Over Time, as Assessed with the CATCH Questionnaire for Pediatric ParticipantsTime frame: At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
- Change from Baseline in the Average Daily Time Spent Doing Physical Activities by Intensity Level Over Time, as Assessed by Participant Responses to the International Physical Activity Questionnaire Short Format (IPAQ-SF)Time frame: At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
- Daily Step Count Over Time, as Measured with a Wearable Activity TrackerTime frame: From Baseline until end of treatment period (up to 36 months)
- Daily Metabolic Equivalents of Tasks (METs) Over Time, as Measured with a Wearable Activity TrackerTime frame: From Baseline until end of treatment period (up to 36 months)
- Daily Time Spent in Moderate to Vigorous Physical Activity (MVPA) Over Time, as per the Activity Tracker Default CategorizationTime frame: From Baseline until end of treatment period (up to 36 months)
- Daily Active Minutes of Physical Activity Over Time, as Measured with a Wearable Activity TrackerTime frame: From Baseline until end of treatment period (up to 36 months)
- Model-Based Annualized Bleed Rates for All Bleeds, Treated Bleeds, Spontaneous Bleeds, Joint Bleeds, Treated Joint Bleeds, and Target Joint BleedsTime frame: From Baseline until end of treatment period (up to 36 months)
- Mean Calculated Annualized Bleed Rates for All Bleeds, Treated Bleeds, Spontaneous Bleeds, Joint Bleeds, Treated Joint Bleeds, and Target Joint BleedsTime frame: From Baseline until end of treatment period (up to 36 months)
- Median Calculated Annualized Bleed Rates for All Bleeds, Treated Bleeds, Spontaneous Bleeds, Joint Bleeds, Treated Joint Bleeds, and Target Joint BleedsTime frame: From Baseline until end of treatment period (up to 36 months)
- Number of Participants who Prefer Emicizumab SC Treatment, Their Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Month 6Time frame: At Month 6
Locations
26 sites in 12 countries. Site status is shown where the registry gives one.
University of Miami Medical Center
Miami, Florida
Oklahoma Children's Hospital ? Jimmy Everest Center
Oklahoma City, Oklahoma
Hospital das Clinicas - UNICAMP
Campinas, São Paulo, Brazil
Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
Ribeirão Preto, São Paulo, Brazil
Hamilton Health Sciences Corporation
Hamilton, Ontario, Canada
Charité Universitätsklinikum Berlin
Berlin, Germany
Universitätsklinikum Bonn
Bonn, Germany
Észak-Pesti Centrumkórház - Honvédkórház
Budapest, Hungary
Policlinico Univ. A. Gemelli
Rome, Lazio, Italy
IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy
AOU Careggi
Florence, Tuscany, Italy
Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique
Rabat, Morocco
University Clinical Centre of Serbia
Belgrade, Serbia
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Vall de Hebron
Barcelona, Spain
Hospital Universitario la Paz
Madrid, Spain
Hospital Regional Universitario Carlos Haya
Málaga, Spain
CHU Farhat Hached
Sousse, Tunisia
Aziza Othmana Hospital
Tunis, Tunisia
Gazi Universitesi Tip Fakultesi
Ankara, Turkey (Türkiye)
Akdeniz Uni School of Medicine
Antalya, Turkey (Türkiye)
Istanbul University Cerrahpasa Medical Faculty
Istanbul, Turkey (Türkiye)
Ege Uni Medical School
Izmir, Turkey (Türkiye)
St Thomas Westminster
London, United Kingdom
Manchester University NHS Foundation Trust (MFT)
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.